Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes.

摘要: The need to consider using dapsone in pregnant women for its antimalarial activity is becoming greater areas where Plasmodium falciparum resistance chloroquine and pyrimethamine-sulfadoxine rapidly increasing. Dapsone combination with other antimalarials might provide a valuable alternative both treatment prophylaxis. This review assesses the clinical pharmacology of adverse drug reactions relation haemolysis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, blood dyscrasias methaemoglobinaemia. Studies are summarised reporting use leprosy, dermatological conditions, malaria, maternal infant outcomes. A total 924 pregnancies were identified during which therapy was taken. Only limited data available this precludes meaningful quantitative benefit-risk analysis. Mild degrees haemolysis consistently occur continued therapy, although effects may be less likely intermittent treatment, as most reported have occurred long-term dapsone. There number gaps knowledge more needed. These include no on pharmacokinetics pregnancy whether these altered co-administration chlorproguanil. Potential complications severe anaemia unknown there information haemolytic or fetus G6PD deficiency. HIV-infected malarious could carry increased risks because immunosuppressive actions drug. Trials should considered good reason deployment. Controlled trials provided tolerance, drugs can offer clear benefit terms improved birthweight. combinations when threat malaria risk.